Cell-free DNA in the management of colorectal cancer

Abstract : Colorectal cancer is one of the leading cause of death by cancer worldwide in both men and women. Liquid biopsy belongs nowadays to the landscape of cancer management biological tools. In this chapter, we will describe and discuss the actual, potential and future applications of cfDNA analysis in plasma of patients with colorectal cancer in early or metastatic stage. During the last decade, the development of molecular biology assays like digital PCR or next-generation sequencing made the analysis of cfDNA in plasma possible with an excellent sensitivity and applications like early detection, diagnosis, prognosis, response to treatment, monitoring of an emerging resistance, mapping of the disease molecular landscape or evaluation of the residual disease are now feasible. cfDNA detection has several promising applications in the management of patients with colorectal cancer, but prospective randomised clinical trials are still lacking to make liquid biopsy ready for prime-time.
Document type :
Book section
Complete list of metadatas

https://hal.univ-lorraine.fr/hal-02325084
Contributor : Alexandre Harlé <>
Submitted on : Tuesday, October 22, 2019 - 10:43:42 AM
Last modification on : Wednesday, October 23, 2019 - 1:33:47 AM

Identifiers

Collections

Citation

Alexandre Harlé. Cell-free DNA in the management of colorectal cancer. Florence Schaffner, Jean-Louis Merlin et Nikolas von Bubnoff. Liquid Biopsy, 215, Springer, pp.253-261, In press, Recent Results in Cancer Research, 978-3-030-26438-3. ⟨10.1007/978-3-030-26439-0_13⟩. ⟨hal-02325084⟩

Share

Metrics

Record views

90